PharmaEngine

PharmaEngine Depreciation & Amortization

Depreciation & Amortization of PharmaEngine (4162.TWO) as of Oct 23, 2026.

Depreciation & Amortization

0.00TWD

Last updated:

Depreciation & Amortization of PharmaEngine is 2025 0.00 TWD. Depreciation & Amortization of PharmaEngine was 2024 0.00 TWD. It decreases by % lower compared to the previous year.

The PharmaEngine Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2018
0.00 TWD
Jan 1, 2019
0.00 TWD
Jan 1, 2020
0.00 TWD
Jan 1, 2021
0.00 TWD
Jan 1, 2022
0.00 TWD
Jan 1, 2023
0.00 TWD
Jan 1, 2024
0.00 TWD
Jan 1, 2025
0.00 TWD
The PharmaEngine Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

On Eulerpool you can find the complete historical development of Depreciation & Amortization PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PharmaEngine

All Key Metrics — PharmaEngine